Niridazole (Ambilhar) was used in the treatment of 20 patients with typhoid fever. The drug was effective in 11 patients. They became afebrile within 5.5 ± 1.5 days. Patients who did not respond were then treated with chloramphenicol and became afebrile within 4.4 ± 10 days. One patient developed a severe drug rash while minor side effects, e. g. headache, nausea, vomiting and aches and pains all over the body, were observed in 4 other patients. The therapy of typhoid fever with niridazole is inferior as compared to chloramphenicol. In vitro niridazole sensitivity tests were carried out in 40 strains of S. typhi and 10 of S. paratyphi which also included the strains isolated in this study. By both disc-diffusion and tube-dilution methods, niridazole was sensitive in concentrations of 20 μ g/disc or 20 μ g/ml.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.